Literature DB >> 22941240

The problem with cardiovascular disease prevention guidelines.

Jay N Cohn1, Daniel A Duprez.   

Abstract

Entities:  

Year:  2012        PMID： 22941240     DOI： 10.1007/s11936-012-0205-6

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN： 1092-8464


× No keyword cloud information.
  25 in total

1.  Preferences and understanding their effects on health.

Authors:  K McPherson; A Britton
Journal:  Qual Health Care       Date:  2001-09

2.  Disclosing industry relationships--toward an improved federal research policy.

Authors:  Eric G Campbell; Darren E Zinner
Journal:  N Engl J Med       Date:  2010-07-14       Impact factor: 91.245

Review 3.  Are there benefits of antihypertensive therapy beyond blood pressure lowering?

Authors:  Joseph L Izzo
Journal:  Curr Hypertens Rep       Date:  2010-12       Impact factor: 5.369

4.  Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial.

Authors:  Inder S Anand; S William Tam; Thomas S Rector; Anne L Taylor; Michael L Sabolinski; W Tad Archambault; Kirkwood F Adams; Adeoye Y Olukotun; Manuel Worcel; Jay N Cohn
Journal:  J Am Coll Cardiol       Date:  2006-12-14       Impact factor: 24.094

Review 5.  Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk.

Authors:  Jennifer G Robinson
Journal:  Am J Cardiol       Date:  2008-04-01       Impact factor: 2.778

6.  Medicine in the era of outcomes measurement.

Authors:  Harlan M Krumholz
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2009-05

7.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.

Authors:  Peter S Sever; Björn Dahlöf; Neil R Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2003-04-05       Impact factor: 79.321

8.  Beneficial effects of valsartan in asymptomatic individuals with vascular or cardiac abnormalities: the DETECTIV Pilot Study.

Authors:  Daniel A Duprez; Natalia D Florea; Kathryn Jones; Jay N Cohn
Journal:  J Am Coll Cardiol       Date:  2007-08-13       Impact factor: 24.094

9.  Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial.

Authors:  Inder S Anand; Thomas S Rector; Michael Kuskowski; Sabu Thomas; N J Holwerda; Jay N Cohn
Journal:  Circ Heart Fail       Date:  2008-05       Impact factor: 8.790

Review 10.  Identifying early cardiovascular disease to target candidates for treatment.

Authors:  Daniel A Duprez; Jay N Cohn
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-03       Impact factor: 3.738
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.